SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* SZABO GABRIEL N (Last) (First) (Middle) C/O CLOSURE MEDICAL CORPORATION 5250 GREENS DAIRY RD. (Street) RALEIGH NC 27616 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CLOSURE MEDICAL CORP [ CLSR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) VP of Product Development
	3. Date of Earliest Transaction (Month/Day/Year) 06/03/2005
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2005		D		2,691	D	$27(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$14.56	06/03/2005		D			20,000	(2)	09/15/2009	Common Stock	20,000	$12.44	0	D
Employee stock option (right to buy)	$19.875	06/03/2005		D			8,000	(3)	09/11/2010	Common Stock	8,000	$7.125	0	D
Employee stock option (right to buy)	$14.875	06/03/2005		D			2,000	(2)	03/26/2011	Common Stock	2,000	$12.125	0	D
Employee stock option (right to buy)	$23.49	06/03/2005		D			2,200	(2)	01/02/2012	Common Stock	2,200	$3.51	0	D
Employee stock option (right to buy)	$14.91	06/03/2005		D			2,200	(2)	06/18/2012	Common Stock	2,200	$12.09	0	D
Employee stock option (right to buy)	$12.06	06/03/2005		D			2,000	(2)	03/11/2013	Common Stock	2,000	$14.94	0	D
Employee stock option (right to buy)	$22.26	06/03/2005		D			10,000	(4)	06/11/2013	Common Stock	10,000	$4.74	0	D
Employee stock option (right to buy)	$19.05	06/03/2005		D			18,000	(4)	12/20/2014	Common Stock	18,000	$7.95	0	D

Explanation of Responses:

1. Amount includes shares acquired under the Employee Stock Purchase Plan at various times and disposed of pursuant to the merger agreement between Closure Medical Corporation, Johnson & Johnson and Holden Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson, in exchange for a cash payment of $27 per share on the effective date of the merger.

2. This option, which provided for vesting in five equal installments commencing on the first anniversary of the date of the grant, was canceled in the merger pursuant to the terms of the merger agreement between Closure Medical Corporation, Johnson & Johnson and Holden Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson, in exchange for a cash payment equal to the difference between $27 and the exercise price of the option.

3. This option, which provided for vesting in three equal installments when each of three increasing stock market prices were achieved, or in any event, in five equal installments commencing on the first anniversary of the date of the grant, was canceled in the merger pursuant to the terms of the merger agreement between Closure Medical Corporation, Johnson & Johnson and Holden Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson, in exchange for a cash payment equal to the difference between $27 and the exercise price of the option.

4. This option, which provided for vesting in four equal installments commencing on the first anniversary of the date of the grant, was canceled in the merger pursuant to the terms of the merger agreement between Closure Medical Corporation, Johnson & Johnson and Holden Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson, in exchange for a cash payment equal to the difference between $27 and the exercise price of the option.

	Angela M. Hudson, Attorney-inFact for Gabriel N. Szabo	06/07/2005
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.